Comparative Pharmacology
Head-to-head clinical analysis: CUTIVATE versus MAGNACORT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CUTIVATE versus MAGNACORT.
CUTIVATE vs MAGNACORT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Glucocorticoid receptor agonist; modulates gene expression to inhibit inflammatory mediators, vasoconstriction, and immunosuppression.
Corticosteroid receptor agonist; modulates gene transcription to produce anti-inflammatory and immunosuppressive effects.
Apply a thin layer to affected skin areas once or twice daily. Therapy should be discontinued when control is achieved; if no improvement is seen within 2 weeks, reassessment of diagnosis may be necessary.
5 mg orally once daily for 7 days, then 5 mg orally every other day for 7 days. Alternatively, 1 mg/kg intravenously every 12 hours for 14 days.
None Documented
None Documented
2-4 hours (terminal elimination half-life); short half-life supports twice-daily dosing for maintenance of clinical effect.
3.5 ± 0.8 hours (terminal); prolonged in renal impairment (up to 12 hours in ESRD) and hepatic disease; requires dose adjustment in CrCl <30 mL/min
Primarily hepatic metabolism; metabolites are excreted renally and fecally. Unchanged drug is negligible in urine. Route: renal (~60% as metabolites), fecal (~40% as metabolites).
Renal (80% as unchanged drug and metabolites, primarily via glomerular filtration and tubular secretion); biliary/fecal (15%)
Category C
Category C
Corticosteroid
Corticosteroid